RayKnowChina Research Map
Shortlist

Cancer

Pancreatic cancer

胰腺癌

Tumours or cancer of the pancreas. Most are malignant; some arise from the hormone-producing islet cells.

Definition adapted from MeSH (US National Library of Medicine)

hospitals in mainland China
192

with a paper from 2016–2025 or a registered study

cities
59

where those hospitals are

open trials in China
269

ClinicalTrials.gov, 18 Nov 2026

Mainland China accounts for 27% of the world's English-language research papers on pancreatic cancer, 2021–2025 (19% in 2016–2020), and 17% of the world's registered trials on it have a site in China.

Research activity in public records, not a rating of care and not medical advice. How the numbers are made

192 hospitals in 59 cities

Order: papers led on pancreatic cancer, 2021–2025, then A–Z. Research activity, not a rating of care.

A hospital is listed when it led at least 6 papers or 1 trial on pancreatic cancer, or was a site in 4 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions

A square is a city. Its size and number are hospitals listed for this disease, not the amount of research. Choose one to show that city in the hospital list and the trial list.

Cities with the most listed hospitals

  1. Shanghai19
  2. Beijing17
  3. Guangzhou13
  4. Hangzhou9
  5. Nanjing7
  6. Chongqing6
  7. Jinan6
  8. Changsha5
  9. Fuzhou5
  10. Shenzhen5

Each opens pancreatic cancer in that city. 49 more cities are in the menu below.

  1. 227 papers led
  2. 212 papers led
  3. 163 papers led
  4. First Affiliated Hospital, Zhejiang University

    浙江大学医学院附属第一医院Hangzhou

    115 papers led
  5. Ruijin Hospital

    上海交通大学医学院附属瑞金医院Shanghai

    114 papers led
  6. Renji Hospital

    上海交通大学医学院附属仁济医院Shanghai

    103 papers led
  7. Jiangsu Province Hospital

    江苏省人民医院(南医大一附院)Nanjing

    91 papers led
  8. Changhai Hospital

    海军军医大学第一附属医院(长海医院)Shanghai

    88 papers led
  9. Zhongshan Hospital, Fudan University

    复旦大学附属中山医院Shanghai

    77 papers led
  10. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    71 papers led
  11. 71 papers led
  12. Union Hospital

    华中科技大学同济医学院附属协和医院Wuhan

    70 papers led
  13. 66 papers led
  14. Tongji Hospital

    华中科技大学同济医学院附属同济医院WuhanInternational Medical Department

    66 papers led
  15. 63 papers led
  16. 60 papers led
    No open trial led
  17. 55 papers led
  18. 54 papers led
  19. 53 papers led
  20. Shengjing Hospital of China Medical University

    中国医科大学附属盛京医院Shenyang

    52 papers led
  21. 47 papers led
    No open trial led
  22. First Hospital of China Medical University

    中国医科大学附属第一医院Shenyang

    46 papers led
    No open trial led
  23. 46 papers led
    No open trial led
  24. 45 papers led
  25. 44 papers led
  26. 44 papers led
    No open trial led
  27. 41 papers led
    No open trial led
  28. 39 papers led
    No open trial led
  29. 39 papers led
  30. 37 papers led
    No open trial led
  31. 37 papers led
    No open trial led
  32. Shanghai General Hospital

    上海市第一人民医院Shanghai

    35 papers led
  33. 34 papers led
  34. Sun Yat-sen Memorial Hospital

    中山大学孙逸仙纪念医院Guangzhou

    34 papers led
    No open trial led
  35. 32 papers led
    No open trial led
  36. Fujian Medical University Union Hospital

    福建医科大学附属协和医院Fuzhou

    32 papers led
    No open trial led
  37. 30 papers led
    No open trial led
  38. 29 papers led
    No open trial led
  39. 29 papers led
    No open trial led
  40. Sir Run Run Shaw Hospital

    浙江大学医学院附属邵逸夫医院Hangzhou

    29 papers led
    No open trial led
  41. 28 papers led
    No open trial led
  42. 28 papers led
    No open trial led
  43. 28 papers led
  44. 27 papers led
    No open trial led
  45. Harbin Medical University Cancer Hospital

    哈尔滨医科大学附属肿瘤医院Harbin

    27 papers led
    No open trial led
  46. Xiangya Hospital

    中南大学湘雅医院Changsha

    26 papers led
  47. 25 papers led
    No open trial led
  48. 23 papers led
    No open trial led
  49. Hangzhou First People's Hospital

    杭州市第一人民医院Hangzhou

    23 papers led
  50. 23 papers led
    No open trial led
  51. 23 papers led
  52. 22 papers led
    No open trial led
  53. 22 papers led
  54. 22 papers led
    No open trial led
  55. Third Xiangya Hospital

    中南大学湘雅三医院Changsha

    22 papers led
  56. Zhongda Hospital, Southeast University

    东南大学附属中大医院Nanjing

    22 papers led
    No open trial led
  57. Hunan Provincial People's Hospital

    湖南省人民医院(湖南师范大学附属第一医院)Changsha

    21 papers led
    No open trial led
  58. 21 papers led
    No open trial led
  59. 21 papers led
    No open trial led
  60. Zhujiang Hospital

    南方医科大学珠江医院Guangzhou

    21 papers led
    No open trial led
  61. First Affiliated Hospital of USTC

    中国科学技术大学附属第一医院(安徽省立医院)Hefei

    20 papers led
    No open trial led
  62. Ningbo Medical Center Lihuili Hospital

    宁波市医疗中心李惠利医院Ningbo

    20 papers led
  63. 20 papers led
    No open trial led
  64. 20 papers led
    No open trial led
  65. 19 papers led
  66. Second Xiangya Hospital

    中南大学湘雅二医院Changsha

    19 papers led
    No open trial led
  67. 18 papers led
    No open trial led
  68. 18 papers led
    No open trial led
  69. 17 papers led
    No open trial led
  70. 16 papers led
    No open trial led
  71. 16 papers led
  72. 16 papers led
    No open trial led
  73. 15 papers led
    No open trial led
  74. 15 papers led
    No open trial led
  75. Shanghai Sixth People's Hospital

    上海市第六人民医院Shanghai

    15 papers led
    No open trial led
  76. China-Japan Union Hospital, Jilin University

    吉林大学白求恩第三医院(中日联谊医院)Changchun

    14 papers led
    No open trial led
  77. 14 papers led
    No open trial led
  78. Shanghai Tenth People's Hospital

    上海市第十人民医院Shanghai

    14 papers led
    No open trial led
  79. Southwest Hospital, Army Medical University

    陆军军医大学第一附属医院(西南医院)Chongqing

    14 papers led
    No open trial led
  80. 13 papers led
    No open trial led
  81. 13 papers led
    No open trial led
  82. Chongqing General Hospital

    重庆大学附属中心医院(重庆市人民医院)Chongqing

    12 papers led
    No open trial led
  83. 12 papers led
    No open trial led
  84. Xinhua Hospital

    上海交通大学医学院附属新华医院Shanghai

    12 papers led
    No open trial led
  85. 11 papers led
    No open trial led
  86. First Affiliated Hospital of Shandong First Medical University

    山东第一医科大学第一附属医院(山东省千佛山医院)Jinan

    11 papers led
    No open trial led
  87. 11 papers led
    No open trial led
  88. 11 papers led
    No open trial led
  89. Huadong Hospital, Fudan University

    复旦大学附属华东医院Shanghai

    11 papers led
  90. Jinling Hospital

    东部战区总医院(金陵医院)Nanjing

    11 papers led
  91. 11 papers led
    No open trial led
  92. 11 papers led
    No open trial led
  93. Shanghai Ninth People's Hospital

    上海交通大学医学院附属第九人民医院Shanghai

    11 papers led
    No open trial led
  94. 11 papers led
    No open trial led
  95. 10 papers led
    No open trial led
  96. 10 papers led
    No open trial led
  97. 10 papers led
    No open trial led
  98. 10 papers led
    No open trial led
  99. Guang'anmen Hospital

    中国中医科学院广安门医院Beijing

    10 papers led
    No open trial led
  100. Henan Cancer Hospital

    河南省肿瘤医院Zhengzhou

    10 papers led
    No open trial led
  101. 10 papers led
    No open trial led
  102. Second Hospital of Dalian Medical University

    大连医科大学附属第二医院Dalian

    10 papers led
    No open trial led
  103. 10 papers led
    No open trial led
  104. Tangdu Hospital

    空军军医大学唐都医院Xi'an

    10 papers led
    No open trial led
  105. 10 papers led
    No open trial led
  106. Xijing Hospital

    空军军医大学西京医院Xi'an

    10 papers led
  107. 9 papers led
    No open trial led
  108. 9 papers led
    No open trial led
  109. 9 papers led
    No open trial led
  110. 9 papers led
    No open trial led
  111. 9 papers led
  112. 9 papers led
  113. 8 papers led
    No open trial led
  114. 8 papers led
    No open trial led
  115. Beijing Tongren Hospital

    首都医科大学附属北京同仁医院Beijing

    8 papers led
    No open trial led
  116. 8 papers led
    No open trial led
  117. 8 papers led
    No open trial led
  118. Nanfang Hospital

    南方医科大学南方医院Guangzhou

    8 papers led
    No open trial led
  119. 8 papers led
    No open trial led
  120. 8 papers led
    No open trial led
  121. 8 papers led
    No open trial led
  122. 8 papers led
    No open trial led
  123. 8 papers led
  124. 7 papers led
    No open trial led
  125. 7 papers led
    No open trial led
  126. Beijing Luhe Hospital

    首都医科大学附属北京潞河医院Beijing

    7 papers led
    No open trial led
  127. Chongqing University Cancer Hospital

    重庆大学附属肿瘤医院Chongqing

    7 papers led
    No open trial led
  128. Eastern Hepatobiliary Surgery Hospital

    海军军医大学第三附属医院(东方肝胆外科医院)Shanghai

    7 papers led
    No open trial led
  129. 7 papers led
    No open trial led
  130. Hainan General Hospital / Hainan Medical University hospitals

    海南医学院附属医院/海南省人民医院Haikou

    7 papers led
    No open trial led
  131. Jiangxi Cancer Hospital

    江西省肿瘤医院Nanchang

    7 papers led
    No open trial led
  132. 7 papers led
    No open trial led
  133. 7 papers led
    No open trial led
  134. 7 papers led
    No open trial led
  135. 7 papers led
    No open trial led
  136. Tianjin Nankai Hospital

    天津市南开医院Tianjin

    7 papers led
    No open trial led
  137. Xinqiao Hospital, Army Medical University

    陆军军医大学第二附属医院(新桥医院)Chongqing

    7 papers led
    No open trial led
  138. 7 papers led
    No open trial led
  139. 6 papers led
    No open trial led
  140. 6 papers led
  141. 6 papers led
    No open trial led
  142. 6 papers led
    No open trial led
  143. 6 papers led
    No open trial led
  144. 6 papers led
    No open trial led
  145. 6 papers led
    No open trial led
  146. 6 papers led
    No open trial led
  147. 6 papers led
    No open trial led
  148. 6 papers led
    No open trial led
  149. Hubei Cancer Hospital

    湖北省肿瘤医院Wuhan

    6 papers led
    No open trial led
  150. Jiangsu Cancer Hospital

    江苏省肿瘤医院Nanjing

    6 papers led
    No open trial led
  151. 6 papers led
    No open trial led
  152. 6 papers led
    No open trial led
  153. 6 papers led
  154. 6 papers led
  155. 6 papers led
    No open trial led
  156. 6 papers led
    No open trial led
  157. Wuxi No.2 People's Hospital

    无锡市第二人民医院Wuxi

    6 papers led
    No open trial led
  158. Xuanwu Hospital

    首都医科大学宣武医院Beijing

    6 papers led
    No open trial led
  159. Yichang Central People's Hospital

    宜昌市中心人民医院Yichang

    6 papers led
    No open trial led
  160. Zhongshan Hospital, Xiamen University

    厦门大学附属中山医院Xiamen

    6 papers led
    No open trial led
  161. 5 papers led
    No open trial led
  162. Fujian Cancer Hospital

    福建省肿瘤医院Fuzhou

    5 papers led
    No open trial led
  163. Sichuan Cancer Hospital

    四川省肿瘤医院Chengdu

    5 papers led
    No open trial led
  164. Yunnan Cancer Hospital

    云南省肿瘤医院Kunming

    5 papers led
    No open trial led
  165. 4 papers led
    No open trial led
  166. Changzheng Hospital

    海军军医大学第二附属医院(长征医院)Shanghai

    4 papers led
  167. 3 papers led
    No open trial led
  168. Hunan Cancer Hospital

    湖南省肿瘤医院Changsha

    3 papers led
  169. Linyi People's Hospital

    临沂市人民医院Linyi

    3 papers led
    No open trial led
  170. 3 papers led
  171. 3 papers led
    No open trial led
  172. Cancer Hospital CAMS – Shenzhen

    中国医学科学院肿瘤医院深圳医院Shenzhen

    2 papers led
  173. Fifth People's Hospital of Fudan University

    复旦大学附属上海市第五人民医院Shanghai

    2 papers led
    No open trial led
  174. 2 papers led
    No open trial led
  175. Hainan Cancer Hospital

    海南省肿瘤医院Haikou

    2 papers led
  176. 2 papers led
    No open trial led
  177. 1 paper led
    No open trial led
  178. 1 paper led
  179. Shanxi Cancer Hospital

    山西省肿瘤医院Taiyuan

    1 paper led
    No open trial led
  180. 1 paper led
    No open trial led
  181. Xuzhou Central Hospital

    徐州市中心医院Xuzhou

    1 paper led
    No open trial led
  182. 0 papers led
    No open trial led
  183. 0 papers led
  184. 0 papers led
    No open trial led
  185. Fuda Cancer Hospital

    广州复大肿瘤医院Guangzhou

    0 papers led
    No open trial led
  186. 0 papers led
  187. 0 papers led
    No open trial led
  188. PLA Navy Anqing Hospital

    中国人民解放军海军安庆医院Anqing

    0 papers led
    No open trial led
  189. PUMC Hospital

    中国医学科学院北京协和医院Beijing

    0 papers led
    No open trial led
  190. Qingdao Central Hospital

    康复大学青岛中心医院Qingdao

    0 papers led
    No open trial led
  191. Shanghai Proton and Heavy Ion Center

    上海市质子重离子医院Shanghai

    0 papers led
  192. Xuzhou Second People's Hospital

    徐州市第二人民医院Xuzhou

    0 papers led
    No open trial led

By university or health system 58

Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.

  1. Fudan University

    复旦大学Shanghai

    347 papers led
    6 hospitals
  2. Shanghai Jiao Tong University School of Medicine

    上海交通大学医学院Shanghai

    309 papers led
    6 hospitals
  3. Peking Union Medical College / Chinese Academy of Medical Sciences

    北京协和医学院/中国医学科学院Beijing

    307 papers led
    6 hospitals
  4. Zhejiang University School of Medicine

    浙江大学医学院Hangzhou

    243 papers led
    6 hospitals
  5. Sichuan University (West China)

    四川大学华西Chengdu

    173 papers led
    4 hospitals
  6. Sun Yat-sen University

    中山大学Guangzhou

    160 papers led
    6 hospitals
  7. Nanjing Medical University

    南京医科大学Nanjing

    154 papers led
    6 hospitals
  8. Huazhong Univ. of Sci. & Tech. – Tongji Medical College

    华中科技大学同济医学院Wuhan

    144 papers led
    4 hospitals
  9. China Medical University (Shenyang)

    中国医科大学Shenyang

    112 papers led
    5 hospitals
  10. Naval Medical University

    海军军医大学Shanghai

    112 papers led
    4 hospitals
  11. Wenzhou Medical University

    温州医科大学Wenzhou

    100 papers led
    6 hospitals
  12. Tianjin Medical University

    天津医科大学Tianjin

    98 papers led
    6 hospitals
  13. Peking University Health Science Center

    北京大学医学部Beijing

    97 papers led
    6 hospitals
  14. Xi'an Jiaotong University

    西安交通大学Xi'an

    85 papers led
    4 hospitals
  15. Nanjing University

    南京大学Nanjing

    80 papers led
    4 hospitals
  16. Fujian Medical University

    福建医科大学Fuzhou

    74 papers led
    6 hospitals
  17. Central South University (Xiangya)

    中南大学湘雅Changsha

    72 papers led
    6 hospitals
  18. Soochow University

    苏州大学Suzhou

    72 papers led
    6 hospitals
  19. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    71 papers led
    1 hospital
  20. Zhengzhou University

    郑州大学Zhengzhou

    71 papers led
    6 hospitals
  21. Harbin Medical University

    哈尔滨医科大学Harbin

    68 papers led
    5 hospitals
  22. Chongqing Medical University

    重庆医科大学Chongqing

    66 papers led
    6 hospitals
  23. Qingdao University

    青岛大学Qingdao

    64 papers led
    5 hospitals
  24. Capital Medical University

    首都医科大学Beijing

    63 papers led
    6 hospitals
  25. Shandong University

    山东大学Jinan

    62 papers led
    5 hospitals
  26. Nanchang University

    南昌大学Nanchang

    56 papers led
    3 hospitals
  27. Wuhan University

    武汉大学Wuhan

    54 papers led
    3 hospitals
  28. Jilin University

    吉林大学Changchun

    50 papers led
    3 hospitals
  29. Shandong First Medical University

    山东第一医科大学Jinan

    50 papers led
    5 hospitals
  30. Guizhou Medical University

    贵州医科大学Guiyang

    42 papers led
    4 hospitals
  31. Southern Medical University

    南方医科大学Guangzhou

    42 papers led
    6 hospitals
  32. Anhui Medical University

    安徽医科大学Hefei

    41 papers led
    6 hospitals
  33. Southwest Medical University

    西南医科大学Luzhou

    41 papers led
    1 hospital
  34. Tongji University

    同济大学Shanghai

    38 papers led
    6 hospitals
  35. Guangxi Medical University

    广西医科大学Nanning

    36 papers led
    4 hospitals
  36. Guangzhou Medical University

    广州医科大学Guangzhou

    34 papers led
    5 hospitals
  37. Shenzhen University

    深圳大学Shenzhen

    30 papers led
    6 hospitals
  38. Nantong University

    南通大学Nantong

    28 papers led
    1 hospital
  39. Air Force Medical University

    空军军医大学Xi'an

    27 papers led
    3 hospitals
  40. Hebei Medical University

    河北医科大学Shijiazhuang

    26 papers led
    4 hospitals
  41. Xiamen University

    厦门大学Xiamen

    26 papers led
    3 hospitals
  42. Army Medical University

    陆军军医大学Chongqing

    25 papers led
    3 hospitals
  43. Kunming Medical University

    昆明医科大学Kunming

    24 papers led
    5 hospitals
  44. University of Chinese Academy of Sciences

    中国科学院大学Beijing

    23 papers led
    1 hospital
  45. 23 papers led
    3 hospitals
  46. 23 papers led
    1 hospital
  47. Chongqing University

    重庆大学Chongqing

    21 papers led
    4 hospitals
  48. 21 papers led
    6 hospitals
  49. Xuzhou Medical University

    徐州医科大学Xuzhou

    19 papers led
    6 hospitals
  50. Jiangnan University

    江南大学Wuxi

    18 papers led
    3 hospitals
  51. Jinan University

    暨南大学Guangzhou

    16 papers led
    4 hospitals
  52. Bengbu Medical University

    蚌埠医科大学Bengbu

    15 papers led
    1 hospital
  53. Ningxia Medical University

    宁夏医科大学Yinchuan

    12 papers led
    1 hospital
  54. Guilin Medical University

    桂林医学院Guilin

    10 papers led
    1 hospital
  55. Guangdong Medical University

    广东医科大学Zhanjiang

    8 papers led
    2 hospitals
  56. Shantou University Medical College

    汕头大学医学院Shantou

    6 papers led
    1 hospital
  57. Xinjiang Medical University

    新疆医科大学Urumqi

    6 papers led
    2 hospitals
  58. Guangdong Pharmaceutical University

    广东药科大学Guangzhou

    2 papers led
    1 hospital

269

open trials on pancreatic cancer in China

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with at least one listed hospital as lead sponsor or site. 196 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.

Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial

What the phases mean (US National Cancer Institute)

  1. Recruiting
    HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07240766

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  2. Recruiting
    HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07296341

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  3. Recruiting
    KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07353645

    Age 18 years to 75 years (registered criteria)

    Led by Nanjing Drum Tower HospitalNanjing

  4. Recruiting
    Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer
    Phase
    N/A
    Started
    2026-06
    Posted
    Registry
    NCT07408505

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  5. Recruiting
    A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
    Phase
    Phase 3
    Started
    2026-02
    Posted
    Registry
    NCT07409272

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  6. Recruiting
    Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer.
    Phase
    Early phase 1
    Started
    2026-02
    Posted
    Registry
    NCT07416240

    Age 18 years to 80 years (registered criteria)

    Led by Hainan Cancer HospitalHaikou

  7. Recruiting
    CAR-NK Cells (CL-NK-003) in Pancreatic Cancer
    Phase
    Phase 1
    Started
    2026-02
    Posted
    Registry
    NCT07425483

    Age 18 years to 75 years (registered criteria)

    Led by Changhai HospitalShanghai

  8. Recruiting
    Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07435038

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  9. Recruiting
    Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07436741

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  10. Recruiting
    A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07438106

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  11. Recruiting
    AI-Powered Precision Decision-Making for Pancreatic Diseases
    Phase
    Not given
    Started
    2026-03
    Posted
    Registry
    NCT07439757

    Age 18 years to 80 years (registered criteria)

    Led by Changhai HospitalShanghai

  12. Recruiting
    IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07483554

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  13. Recruiting
    To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement.
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07493421

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  14. Recruiting
    Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07504471

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  15. Recruiting
    Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07529626

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 2 listed hospitals as study sitesChangsha, Shanghai, Xi'an

  16. Recruiting
    Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
    Phase
    Not given
    Started
    2026-04
    Posted
    Registry
    NCT07552467

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  17. Recruiting
    18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07557225

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  18. Recruiting
    Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2026-03
    Posted
    Registry
    NCT07589205

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  19. Recruiting
    An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07589569

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Tianjin

  20. Recruiting
    NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07595172

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  21. Recruiting
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07610798

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  22. Recruiting
    Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07632118

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  23. Recruiting
    Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07640295

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Harbin, Nanjing, Shanghai, Taiyuan, Wuhan, Zhengzhou

  24. Recruiting
    A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer
    Phase
    Early phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07649928

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  25. Recruiting
    Spatial Multi-omics and Intelligent Early Warning of Pancreatic Cancer Cachexia
    Phase
    Not given
    Started
    2026-04
    Posted
    Registry
    NCT07670286

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  26. Recruiting
    A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07678593

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou

  27. Recruiting
    SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07683221

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  28. Recruiting
    Patient-Derived Organoid-on-a-Chip Model for Personalized Prediction of Chemotherapy Efficacy in Pancreatic Cancer
    Phase
    Not given
    Started
    2026-02
    Posted
    Registry
    NCT07683845

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  29. Recruiting
    A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
    Phase
    Early phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07707531

    Age 18 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

  30. Recruiting
    68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07760012

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Third HospitalBeijing

  31. Recruiting
    YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies
    Phase
    Phase 1
    Started
    2026-08
    Posted
    Registry
    NCT07763301

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  32. Recruiting
    A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07784374

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  33. Recruiting
    IRE After Chemotherapy for Locally Advanced Pancreatic Cancer
    Phase
    N/A
    Started
    2026-05
    Posted
    Registry
    NCT07799935

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  34. Recruiting
    GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDAC
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07802184

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  35. Recruiting
    An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07806058

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  36. Recruiting
    Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard Therapy
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07892573

    Age 18 years to 85 years (registered criteria)

    Led by Ningbo Medical Center Lihuili HospitalNingbo

  37. Recruiting
    Liver Metastasis in Pancreatic Ductal Adenocarcinoma: Regulatory Mechanisms and Clinical Significance
    Phase
    Not given
    Started
    2026-10
    Posted
    Registry
    NCT07933952

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital of Nanjing Medical UniversityNanjing

  38. Recruiting
    Nectin-4 Specific LMW PET Probe Imaging in Multiple Solid Tumors
    Phase
    N/A
    Started
    2025-05
    Posted
    Registry
    NCT05321316

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  39. Recruiting
    Pancreatic Cancer and Diabetes Mellitus
    Phase
    Not given
    Started
    2025-01
    Posted
    Registry
    NCT06585072

    Age 18 years to Not stated (registered criteria)

    Led by Changzheng HospitalShanghai

  40. Recruiting
    Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06752811

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  41. Recruiting
    A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06758544

    Age 18 years to 75 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  42. Recruiting
    IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06770439

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  43. Recruiting
    HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06770452

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  44. Recruiting
    Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06789679

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  45. Recruiting
    CAR-NK Cells (CL-NK-001) in Pancreatic Cancer
    Phase
    Phase 1
    Started
    2025-04
    Posted
    Registry
    NCT06816823

    Age 18 years to 70 years (registered criteria)

    Led by Changhai HospitalShanghai

  46. Recruiting
    Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06821503

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Harbin, Nanchang, Nanjing, Shanghai, Shenyang, Tianjin, Xi'an, Zhengzhou

  47. Recruiting
    A Study of GC203 TIL in PDCA (RJ)
    Phase
    Early phase 1
    Started
    2025-02
    Posted
    Registry
    NCT06828328

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  48. Recruiting
    Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer.
    Phase
    N/A
    Started
    2025-03
    Posted
    Registry
    NCT06840067

    Age 18 years to 80 years (registered criteria)

    Led by Gansu Wuwei Tumor HospitalWuwei

  49. Recruiting
    Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06844422

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  50. Recruiting
    The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)
    Phase
    Phase 1
    Started
    2025-03
    Posted
    Registry
    NCT06861543

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  51. Recruiting
    Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06895031

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  52. Recruiting
    A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
    Phase
    Phase 1
    Started
    2025-03
    Posted
    Registry
    NCT06898385

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  53. Recruiting
    18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT06937112

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  54. Recruiting
    An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06938282

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  55. Recruiting
    A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06944106

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  56. Recruiting
    The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06946901

    Age 18 years to 80 years (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 1 listed hospital as study siteChangsha, Shanghai

  57. Recruiting
    QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06951997

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  58. Recruiting
    A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06953999

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHangzhou, Harbin, Shanghai

  59. Recruiting
    A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06962267

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  60. Recruiting
    Adjuvant Pancreatic Therapy Guided by MRD
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT06966440

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  61. Recruiting
    A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
    Phase
    Phase 2/Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT06989437

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Lanzhou, Shanghai, Taiyuan, Wenzhou, Xi'an, Zhengzhou

  62. Recruiting
    Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT07006077

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  63. Recruiting
    The Characteristics of Oral Microbiota in Chronic Pancreatitis and Autoimmune Pancreatitis
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT07015580

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  64. Recruiting
    Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution
    Phase
    Not given
    Started
    2025-05
    Posted
    Registry
    NCT07034339

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  65. Recruiting
    A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT07040228

    Age 18 years to 80 years (registered criteria)

    Led by Cancer Hospital CAMS – ShenzhenShenzhen

  66. Recruiting
    A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07066098

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  67. Recruiting
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07066657

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Harbin, Shanghai, Wuhan, Zhengzhou

  68. Recruiting
    A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07079228

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  69. Recruiting
    A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer
    Phase
    Not given
    Started
    2025-05
    Posted
    Registry
    NCT07080021

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  70. Recruiting
    A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-08
    Posted
    Registry
    NCT07090499

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  71. Recruiting
    A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT07101679

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  72. Recruiting
    A Study of GV20-0251 in Advanced or Refractory Solid Tumors
    Phase
    Phase 1
    Started
    2025-09
    Posted
    Registry
    NCT07106827

    Age 18 years to Not stated (registered criteria)

    Led by West China HospitalChengdu

  73. Recruiting
    QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07110064

    Age 18 years to Not stated (registered criteria)

    Led by Nanjing Drum Tower HospitalNanjing

  74. Recruiting
    A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07114315

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Tianjin

  75. Recruiting
    Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
    Phase
    Not given
    Started
    2025-08
    Posted
    Registry
    NCT07117045

    Age 50 years to Not stated (registered criteria)

    Led by Changhai HospitalShanghai

  76. Recruiting
    HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07131514

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  77. Recruiting
    PGHD-AI Intelligent Model for the Nutritional Assessment and Intervention of Patients After Radical Surgery for Pancreatic Cancer.
    Phase
    N/A
    Started
    2025-07
    Posted
    Registry
    NCT07167264

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  78. Recruiting
    Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07173387

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  79. Recruiting
    A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer
    Phase
    Early phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07198659

    Age 18 years to 70 years (registered criteria)

    Led by Xijing HospitalXi'an

  80. Recruiting
    HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07232875

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  81. Recruiting
    Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07235930

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  82. Recruiting
    Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07238283

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  83. Recruiting
    A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07255404

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Kunming, Nanchang, Shanghai, Shenyang, Wuhan, Zhengzhou

  84. Recruiting
    Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07262567

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  85. Recruiting
    Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07301814

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  86. Recruiting
    IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07306273

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  87. Recruiting
    Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07306286

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  88. Recruiting
    LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07312422

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Provincial People's HospitalHangzhou

  89. Recruiting
    A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07326137

    Age not stated (registered criteria)

    Led by Tongji HospitalWuhan

  90. Recruiting
    68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07331532

    Age 18 years to 80 years (registered criteria)

    Led by Peking University First HospitalBeijing

  91. Recruiting
    Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
    Phase
    Not given
    Started
    2025-11
    Posted
    Registry
    NCT07359586

    Age not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  92. Recruiting
    Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors:A Prospective Exploratory Study
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT07542002

    Age 18 years to 75 years (registered criteria)

    Led by Ningbo Medical Center Lihuili HospitalNingbo

  93. Recruiting
    A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07561814

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  94. Recruiting
    Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07586813

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  95. Recruiting
    To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
    Phase
    Phase 1
    Started
    2025-08
    Posted
    Registry
    NCT07594964

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  96. Recruiting
    A IIT Study of 177Lu-DOTA-SNA040
    Phase
    Early phase 1
    Started
    2025-11
    Posted
    Registry
    NCT07595237

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  97. Recruiting
    Preliminary Trial of SNA014 for Pancreatic Cancer
    Phase
    Early phase 1
    Started
    2025-10
    Posted
    Registry
    NCT07597772

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  98. Recruiting
    Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07600268

    Age 18 years to 70 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  99. Recruiting
    IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT07692750

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  100. Recruiting
    Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07823049

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yangzhou, Yinchuan, Zhengzhou

  101. Recruiting
    NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
    Phase
    Phase 1
    Started
    2024-11
    Posted
    Registry
    NCT06134960

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  102. Recruiting
    A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
    Phase
    Phase 2
    Started
    2024-02
    Posted
    Registry
    NCT06172478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou

  103. Recruiting
    GPC3/Mesothelin-CAR-γδT Cells Against Cancers
    Phase
    Phase 1
    Started
    2024-05
    Posted
    Registry
    NCT06196294

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  104. Recruiting
    Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)
    Phase
    Not given
    Started
    2024-03
    Posted
    Registry
    NCT06277531

    Age 18 years to 85 years (registered criteria)

    Led by Peking University Third Hospital; 1 listed hospital as study siteBeijing

  105. Recruiting
    Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases
    Phase
    Phase 1
    Started
    2024-01
    Posted
    Registry
    NCT06278454

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChongqing, Shanghai, Suzhou, Tianjin, Zhengzhou

  106. Recruiting
    Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
    Phase
    Early phase 1
    Started
    2024-04
    Posted
    Registry
    NCT06326736

    Age 18 years to 75 years (registered criteria)

    Led by Jinling HospitalNanjing

  107. Recruiting
    Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer
    Phase
    Phase 1
    Started
    2024-04
    Posted
    Registry
    NCT06344156

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  108. Recruiting
    XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
    Phase
    N/A
    Started
    2024-03
    Posted
    Registry
    NCT06353646

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  109. Recruiting
    PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06359275

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  110. Recruiting
    A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06361888

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Suzhou, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  111. Recruiting
    Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
    Phase
    Not given
    Started
    2024-04
    Posted
    Registry
    NCT06375473

    Age 18 years to 100 years (registered criteria)

    Led by Peking Union Medical College Hospital; 7 listed hospitals as study sitesBeijing, Hefei, Nanning, Ningbo, Shanghai, Wuhan, Zhengzhou

  112. Recruiting
    A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-04
    Posted
    Registry
    NCT06403735

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHarbin, Kunming, Nanchang, Shanghai

  113. Recruiting
    Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06427239

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  114. Recruiting
    Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)
    Phase
    Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06427447

    Age 18 years to 75 years (registered criteria)

    Led by Changhai HospitalShanghai

  115. Recruiting
    Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06427460

    Age 18 years to 75 years (registered criteria)

    Led by Changhai HospitalShanghai

  116. Recruiting
    A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06428409

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Shanghai, Wuhan

  117. Recruiting
    Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06435260

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  118. Recruiting
    Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06454448

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  119. Recruiting
    A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT06465069

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  120. Recruiting
    Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer
    Phase
    N/A
    Started
    2024-05
    Posted
    Registry
    NCT06478225

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  121. Recruiting
    Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06491472

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  122. Recruiting
    NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer
    Phase
    N/A
    Started
    2024-04
    Posted
    Registry
    NCT06494514

    Age 18 years to Not stated (registered criteria)

    Led by Nanjing Drum Tower HospitalNanjing

  123. Recruiting
    Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer
    Phase
    Early phase 1
    Started
    2024-07
    Posted
    Registry
    NCT06496373

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  124. Recruiting
    A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT06500052

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  125. Recruiting
    Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer
    Phase
    N/A
    Started
    2024-08
    Posted
    Registry
    NCT06515587

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  126. Recruiting
    Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06531278

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  127. Recruiting
    Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06532617

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  128. Recruiting
    Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06534762

    Age 18 years to 65 years (registered criteria)

    Led by Zhejiang Provincial People's HospitalHangzhou

  129. Recruiting
    A New Strategy for Preoperative Drainage of Resectable Pancreatic Head Cancer Combined Severe Obstructive Jaundice
    Phase
    N/A
    Started
    2024-08
    Posted
    Registry
    NCT06541340

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  130. Recruiting
    Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06547736

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  131. Recruiting
    Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06572813

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  132. Recruiting
    Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors
    Phase
    Early phase 1
    Started
    2024-09
    Posted
    Registry
    NCT06577532

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  133. Recruiting
    Irinotecan Liposome in Combination With Capecitabine
    Phase
    N/A
    Started
    2024-08
    Posted
    Registry
    NCT06578052

    Age 18 years to 80 years (registered criteria)

    Led by Cancer Hospital CAMS – ShenzhenShenzhen

  134. Recruiting
    Adebrelimab and Chidamide for Pancreatic Cancer
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06584227

    Age 18 years to 75 years (registered criteria)

    Led by Jinling HospitalNanjing

  135. Recruiting
    HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06587061

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  136. Recruiting
    Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-09
    Posted
    Registry
    NCT06596915

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  137. Recruiting
    The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
    Phase
    Not given
    Started
    2024-09
    Posted
    Registry
    NCT06601010

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  138. Recruiting
    ImmunoPET Imaging of Pancreatic Cancer
    Phase
    N/A
    Started
    2024-11
    Posted
    Registry
    NCT06602037

    Age 18 years to 70 years (registered criteria)

    Led by Renji HospitalShanghai

  139. Recruiting
    AI-Assisted Non-Contrast CT for Multi-Cancer Screening
    Phase
    N/A
    Started
    2024-10
    Posted
    Registry
    NCT06632886

    Age 18 years to Not stated (registered criteria)

    Led by Changhai HospitalShanghai

  140. Recruiting
    AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
    Phase
    Not given
    Started
    2024-08
    Posted
    Registry
    NCT06638866

    Age 18 years to Not stated (registered criteria)

    Led by Changhai Hospital; 1 listed hospital as study siteJiaxing, Shanghai

  141. Recruiting
    Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06662006

    Age 18 years to 75 years (registered criteria)

    Led by Nanjing Drum Tower HospitalNanjing

  142. Recruiting
    Target-specific immunoPET Imaging of Digestive System Carcinoma
    Phase
    N/A
    Started
    2024-12
    Posted
    Registry
    NCT06715839

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  143. Recruiting
    Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06722911

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Provincial People's HospitalHangzhou

  144. Recruiting
    A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer
    Phase
    Phase 1
    Started
    2024-12
    Posted
    Registry
    NCT06760364

    Age 18 years to 70 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  145. Recruiting
    mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
    Phase
    Phase 1/Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06761027

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial Hospital; 1 listed hospital as study siteFuzhou

  146. Recruiting
    Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06767813

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesNanjing, Shanghai, Suzhou, Wenzhou, Zhengzhou

  147. Recruiting
    Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06782685

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  148. Recruiting
    Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT06821048

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  149. Recruiting
    Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
    Phase
    Not given
    Started
    2024-10
    Posted
    Registry
    NCT06843629

    Age 18 years to 65 years (registered criteria)

    Led by Union HospitalWuhan

  150. Recruiting
    A Study of JMT203 in Patients With Cancer Cachexia
    Phase
    Phase 1/Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06868849

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  151. Recruiting
    CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
    Phase
    Early phase 1
    Started
    2024-12
    Posted
    Registry
    NCT06937567

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  152. Recruiting
    Bile Omics for Diagnosing Indeterminate Biliary Strictures
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT07007832

    Age 18 years to 90 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  153. Recruiting
    CtDNA-guided Maintenance Therapy in Pancreatic Cancer
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT07054879

    Age 18 years to Not stated (registered criteria)

    Led by Nanjing Drum Tower HospitalNanjing

  154. Recruiting
    Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT07433283

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Haikou, Harbin, Shanghai, Zhengzhou

  155. Recruiting
    Artificial Intelligence-Assisted 4D Dynamic Long-Axial PET Imaging for the Detection of Early Pancreatic Cancer Lesions
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT07925125

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  156. Recruiting
    Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples
    Phase
    Not given
    Started
    2023-03
    Posted
    Registry
    NCT05737953

    Age 18 years to Not stated (registered criteria)

    Led by Changhai HospitalShanghai

  157. Recruiting
    Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
    Phase
    Phase 1
    Started
    2023-03
    Posted
    Registry
    NCT05779917

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  158. Recruiting
    The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer
    Phase
    N/A
    Started
    2023-02
    Posted
    Registry
    NCT05802394

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  159. Recruiting
    The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
    Phase
    N/A
    Started
    2023-02
    Posted
    Registry
    NCT05802407

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  160. Recruiting
    Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors
    Phase
    Not given
    Started
    2023-02
    Posted
    Registry
    NCT05847855

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 1 listed hospital as study siteChengdu, Shanghai

  161. Recruiting
    A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
    Phase
    Phase 2
    Started
    2023-05
    Posted
    Registry
    NCT05859750

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan, Shanghai, Wuhan

  162. Recruiting
    Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma
    Phase
    N/A
    Started
    2023-08
    Posted
    Registry
    NCT05869474

    Age 18 years to 80 years (registered criteria)

    Led by Changhai HospitalShanghai

  163. Recruiting
    A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
    Phase
    Phase 1
    Started
    2023-07
    Posted
    Registry
    NCT05911217

    Age 18 years to 79 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai, Wuhan, Xi'an, Zhengzhou

  164. Recruiting
    Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer
    Phase
    Early phase 1
    Started
    2023-04
    Posted
    Registry
    NCT05916261

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  165. Recruiting
    LRAMPS Versus LDP in Selected Early-stage Left-sided Pancreatic Cancer
    Phase
    N/A
    Started
    2023-10
    Posted
    Registry
    NCT05939063

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  166. Recruiting
    A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT05969171

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  167. Recruiting
    A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT06008288

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Zhengzhou

  168. Recruiting
    A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2023-08
    Posted
    Registry
    NCT06043466

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou

  169. Recruiting
    Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
    Phase
    Phase 2
    Started
    2023-08
    Posted
    Registry
    NCT06050317

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  170. Recruiting
    A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT06111274

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Harbin, Shanghai, Wuhan

  171. Recruiting
    Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2023-11
    Posted
    Registry
    NCT06126406

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhu

  172. Recruiting
    A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-11
    Posted
    Registry
    NCT06131840

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  173. Recruiting
    Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers
    Phase
    Not given
    Started
    2023-11
    Posted
    Registry
    NCT06139042

    Age 40 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  174. Recruiting
    Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery
    Phase
    N/A
    Started
    2023-03
    Posted
    Registry
    NCT06164769

    Age 14 years to 70 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  175. Recruiting
    A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection
    Phase
    Not given
    Started
    2023-12
    Posted
    Registry
    NCT06166147

    Age 40 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesShanghai

  176. Recruiting
    Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06199895

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  177. Recruiting
    Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis
    Phase
    N/A
    Started
    2023-10
    Posted
    Registry
    NCT06307080

    Age 18 years to 70 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  178. Recruiting
    A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-04
    Posted
    Registry
    NCT06508307

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  179. Recruiting
    Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
    Phase
    Phase 1/Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06799637

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Kunming, Luoyang, Shanghai, Wuhan

  180. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Posted
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  181. Recruiting
    Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
    Phase
    Phase 1/Phase 2
    Started
    2022-04
    Posted
    Registry
    NCT05288205

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Harbin, Hefei, Jinan, Shanghai, Shenyang, Shenzhen, Wuhan, Xiamen, Zhengzhou

  182. Recruiting
    A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
    Phase
    Phase 1
    Started
    2022-06
    Posted
    Registry
    NCT05365581

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Wuhan, Zhengzhou

  183. Recruiting
    Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer
    Phase
    N/A
    Started
    2022-07
    Posted
    Registry
    NCT05424159

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Proton and Heavy Ion CenterShanghai

  184. Recruiting
    Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
    Phase
    N/A
    Started
    2022-10
    Posted
    Registry
    NCT05620732

    Age 18 years to 75 years (registered criteria)

    Led by Shenzhen University General HospitalShenzhen

  185. Recruiting
    Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
    Phase
    Phase 3
    Started
    2022-12
    Posted
    Registry
    NCT05653453

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHarbin, Shanghai

  186. Recruiting
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    Phase
    Not given
    Started
    2022-09
    Posted
    Registry
    NCT06822413

    Age not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai

  187. Recruiting
    MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer
    Phase
    Not given
    Started
    2022-10
    Posted
    Registry
    NCT07045571

    Age not stated (registered criteria)

    Led by Renji HospitalShanghai

  188. Recruiting
    Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
    Phase
    Phase 1/Phase 2
    Started
    2021-10
    Posted
    Registry
    NCT04146298

    Age 18 years to 75 years (registered criteria)

    Led by Changhai HospitalShanghai

  189. Recruiting
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2021-06
    Posted
    Registry
    NCT04900818

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  190. Recruiting
    Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
    Phase
    Phase 4
    Started
    2021-03
    Posted
    Registry
    NCT05035147

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  191. Recruiting
    A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)
    Phase
    Early phase 1
    Started
    2021-09
    Posted
    Registry
    NCT05098197

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  192. Recruiting
    Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Posted
    Registry
    NCT05187338

    Age 18 years to 70 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  193. Recruiting
    Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
    Phase
    Phase 1/Phase 2
    Started
    2021-08
    Posted
    Registry
    NCT05218889

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  194. Recruiting
    Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)
    Phase
    Not given
    Started
    2020-12
    Posted
    Registry
    NCT04743479

    Age 50 years to 75 years (registered criteria)

    Led by Changhai HospitalShanghai

  195. Recruiting
    MRE for Diagnosis of Pancreatic Masses
    Phase
    Not given
    Started
    2020-10
    Posted
    Registry
    NCT06526442

    Age 18 years to 80 years (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  196. Recruiting
    Assessment of the Prognosis of Pancreatic Cancer Patients Using 3D MRE
    Phase
    Not given
    Started
    2020-10
    Posted
    Registry
    NCT06849063

    Age 18 years to 80 years (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  197. Recruiting
    Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma
    Phase
    N/A
    Started
    2019-03
    Posted
    Registry
    NCT03785743

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  198. Recruiting
    mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
    Phase
    Phase 2
    Started
    2019-09
    Posted
    Registry
    NCT04084496

    Age 18 years to 79 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  199. Recruiting
    Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer
    Phase
    Phase 2
    Started
    2018-04
    Posted
    Registry
    NCT03498326

    Age 18 years to 90 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  200. Recruiting
    The Comparision of Minimally-invasive and Open Pancreaticoduodenectomy for Pancreatic Cancer
    Phase
    N/A
    Started
    2018-12
    Posted
    Registry
    NCT03747588

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  201. Recruiting
    Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
    Phase
    Phase 2/Phase 3
    Started
    2018-11
    Posted
    Registry
    NCT03755739

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  202. Not yet recruiting
    A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer
    Phase
    Phase 3
    Started
    2027-01
    Posted
    Registry
    NCT07138846

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  203. Not yet recruiting
    A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07014878

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  204. Not yet recruiting
    JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07175389

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  205. Not yet recruiting
    Study on Efficacy and Safety of VMAT Technique With Local Dose Escalation for Unresectable Pancreatic Cancer
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07242911

    Age 18 years to 76 years (registered criteria)

    Led by Chifeng Tumor HospitalChifeng

  206. Not yet recruiting
    A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer
    Phase
    Phase 3
    Started
    2026-02
    Posted
    Registry
    NCT07383922

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  207. Not yet recruiting
    Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer
    Phase
    Early phase 1
    Started
    2026-09
    Posted
    Registry
    NCT07394205

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou

  208. Not yet recruiting
    IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07415525

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  209. Not yet recruiting
    EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases
    Phase
    Not given
    Started
    2026-03
    Posted
    Registry
    NCT07448376

    Age 18 years to 70 years (registered criteria)

    Led by Tongji HospitalWuhan

  210. Not yet recruiting
    Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07469956

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  211. Not yet recruiting
    Chimeric Antigen Receptor Macrophages Targeting c-MET for Advanced Stage of Pancreatic Cancer Patients
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07553793

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  212. Not yet recruiting
    Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging
    Phase
    Not given
    Started
    2026-04
    Posted
    Registry
    NCT07554742

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  213. Not yet recruiting
    A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07583771

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  214. Not yet recruiting
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07623642

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin

  215. Not yet recruiting
    Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
    Phase
    Phase 1
    Started
    2026-07
    Posted
    Registry
    NCT07624214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  216. Not yet recruiting
    Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07637786

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  217. Not yet recruiting
    HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
    Phase
    Phase 1
    Started
    2026-07
    Posted
    Registry
    NCT07699757

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  218. Not yet recruiting
    Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07745790

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  219. Not yet recruiting
    Baduanjin for Quality of Life in Pancreatic Cancer Chemotherapy
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07791550

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  220. Not yet recruiting
    Five-Element Music Therapy for Psychological Distress in Pancreatic Cancer Chemotherapy
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07796906

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  221. Not yet recruiting
    Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07814859

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  222. Not yet recruiting
    Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07825753

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  223. Not yet recruiting
    Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07828756

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  224. Not yet recruiting
    Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07833241

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  225. Not yet recruiting
    Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07875465

    Age 18 years to Not stated (registered criteria)

    Led by Hangzhou Cancer HospitalHangzhou

  226. Not yet recruiting
    Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation
    Phase
    Phase 1
    Started
    2026-10
    Posted
    Registry
    NCT07875920

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  227. Not yet recruiting
    HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07900789

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai

  228. Not yet recruiting
    A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants
    Phase
    Phase 1
    Started
    2026-11
    Posted
    Registry
    NCT07906691

    Age 18 years to 45 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha

  229. Not yet recruiting
    A Multicenter, Prospective Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreatic Cancer
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07928362

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin Hospital; 4 listed hospitals as study sitesChengdu, Qingdao, Shanghai, Xi'an

  230. Not yet recruiting
    Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT05562297

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  231. Not yet recruiting
    Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT06177522

    Age 18 years to 80 years (registered criteria)

    Led by Jinling HospitalNanjing

  232. Not yet recruiting
    QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06750861

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  233. Not yet recruiting
    Validation of Joint-AI in Diagnosing Pancreatic Solid Lesions
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT06753318

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  234. Not yet recruiting
    Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06759090

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  235. Not yet recruiting
    Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis
    Phase
    Phase 4
    Started
    2025-07
    Posted
    Registry
    NCT06779318

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  236. Not yet recruiting
    Chemoradiotherapy in Elderly Patients with Locally Advanced Pancreatic Cancer (70+).
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06844773

    Age 70 years to 85 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  237. Not yet recruiting
    A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06866977

    Age 18 years to Not stated (registered criteria)

    Led by Xiangya HospitalChangsha

  238. Not yet recruiting
    Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06888648

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  239. Not yet recruiting
    Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06888674

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  240. Not yet recruiting
    A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT06913218

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  241. Not yet recruiting
    Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06916975

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  242. Not yet recruiting
    Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT06941987

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  243. Not yet recruiting
    Clinical Study on Fecal Microbiota Transplantation for Diarrhea After Total Pancreatectomy
    Phase
    N/A
    Started
    2025-05
    Posted
    Registry
    NCT06960122

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  244. Not yet recruiting
    22G-Adapt vs 22G-Franseen Needle Biopsy in EUS-Guided Tissue Acquisition of Solid Lesions
    Phase
    N/A
    Started
    2025-07
    Posted
    Registry
    NCT07012694

    Age 18 years to 85 years (registered criteria)

    Led by Tongji HospitalWuhan

  245. Not yet recruiting
    Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT07014254

    Age 18 years to 80 years (registered criteria)

    Led by Xijing HospitalXi'an

  246. Not yet recruiting
    A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastatic Pancreatic Cancer in China
    Phase
    Not given
    Started
    2025-07
    Posted
    Registry
    NCT07026123

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  247. Not yet recruiting
    XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer
    Phase
    N/A
    Started
    2025-08
    Posted
    Registry
    NCT07114666

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  248. Not yet recruiting
    Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors
    Phase
    N/A
    Started
    2025-10
    Posted
    Registry
    NCT07172503

    Age 18 years to 70 years (registered criteria)

    Led by Union HospitalWuhan

  249. Not yet recruiting
    A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer
    Phase
    Early phase 1
    Started
    2025-11
    Posted
    Registry
    NCT07231094

    Age 18 years to Not stated (registered criteria)

    Led by Third Xiangya HospitalChangsha

  250. Not yet recruiting
    A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07233850

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  251. Not yet recruiting
    Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07277452

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  252. Not yet recruiting
    Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino
    Phase
    Early phase 1
    Started
    2024-01
    Posted
    Registry
    NCT06156267

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  253. Not yet recruiting
    Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer
    Phase
    Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT06166589

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  254. Not yet recruiting
    HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer
    Phase
    Phase 3
    Started
    2024-02
    Posted
    Registry
    NCT06217042

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  255. Not yet recruiting
    Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients
    Phase
    Phase 2
    Started
    2024-02
    Posted
    Registry
    NCT06234072

    Age 18 years to Not stated (registered criteria)

    Led by Shenzhen University General HospitalShenzhen

  256. Not yet recruiting
    Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC
    Phase
    Phase 1
    Started
    2024-05
    Posted
    Registry
    NCT06346808

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  257. Not yet recruiting
    Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06361030

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  258. Not yet recruiting
    Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
    Phase
    Phase 1/Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06370754

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  259. Not yet recruiting
    Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06409429

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  260. Not yet recruiting
    Early Diagnosis of Pancreatic Cancer Via Deciphering Multi-modal Immunological Signatures
    Phase
    Not given
    Started
    2024-08
    Posted
    Registry
    NCT06495749

    Age not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  261. Not yet recruiting
    Research of the Application of Artificial Intelligence Model "PANDA"
    Phase
    N/A
    Started
    2024-08
    Posted
    Registry
    NCT06528223

    Age not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  262. Not yet recruiting
    Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06531291

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  263. Not yet recruiting
    A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
    Phase
    Phase 1
    Started
    2024-11
    Posted
    Registry
    NCT06614751

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  264. Not yet recruiting
    TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
    Phase
    Early phase 1
    Started
    2024-09
    Posted
    Registry
    NCT06619886

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  265. Not yet recruiting
    Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06621095

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  266. Not yet recruiting
    Canagliflozin With Gemcitabine in Pancreatic Carcinoma
    Phase
    N/A
    Started
    2023-10
    Posted
    Registry
    NCT05903703

    Age 18 years to Not stated (registered criteria)

    Led by Hangzhou First People's HospitalHangzhou

  267. Enrolling by invitation
    Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07386704

    Age 18 years to 80 years (registered criteria)

    Led by Peking University First HospitalBeijing

  268. Enrolling by invitation
    Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary Carcinoma
    Phase
    N/A
    Started
    2023-07
    Posted
    Registry
    NCT06076252

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang

  269. Enrolling by invitation
    The Differences of Complications Between LPD(Laparoscopic Pancreaticoduodenectomy) and OPD(Open Pancreaticoduodenectomy)
    Phase
    Not given
    Started
    2020-01
    Posted
    Registry
    NCT06685939

    Age 19 years to Not stated (registered criteria)

    Led by Huadong Hospital, Fudan UniversityShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Additional research sources

Read the linked papers and reports

Where these numbers come from

Papers

5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search

Trials

ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 18 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data (CSV)Definitions